论文部分内容阅读
目的探讨低剂量沙美特罗/氟替卡松干粉剂(舒利迭)吸入治疗成人咳嗽变异性哮喘的临床疗效及药物安全性。方法 120例咳嗽变异性哮喘成人患者随机分为研究组和对照组,各60例,两组患者均给予针对咳嗽变异性哮喘的常规治疗措施,研究组患者同时吸入低剂舒利迭治疗,而对照组吸入丙酸倍氯米松气雾剂,对两组患者治疗效果及药物安全性进行综合比较。结果研究组患者在治疗第1、2、3周时的咳嗽症状消失率均高于同期对照组(P<0.05);两组患者治疗前晨间呼气峰值流速(PEF)比较差异无统计学意义(P>0.05),经有效治疗4周后,研究组晨间PEF明显高于对照组(P<0.05);两组患者均无严重的药物不良反应情况发生。结论吸入低剂量舒利迭治疗成人咳嗽变异性哮喘能明显缓解患者咳嗽症状,改善肺功能,安全性高。
Objective To investigate the clinical efficacy and drug safety of low-dose salmeterol / fluticasone dry powder inhalation for adult cough variant asthma. Methods A total of 120 adults with cough variant asthma were randomly divided into study group and control group, 60 cases in each group. Both groups were given routine treatment for cough variant asthma. Patients in study group were also treated with low dose of seretide while Control group inhaled beclometasone dipropionate aerosol, the treatment effect of two groups of patients and drug safety comprehensive comparison. Results The disappearance rate of cough in the study group was higher than that in the control group at the first and second week (P <0.05). There was no significant difference in the peak expiratory flow (PEF) between the two groups before treatment (P> 0.05). After 4 weeks of effective treatment, the morning PEF in the study group was significantly higher than that in the control group (P <0.05). No serious adverse drug reaction occurred in both groups. Conclusion Inhalation of low-dose seretide for adult cough variant asthma can significantly relieve the symptoms of cough in patients and improve lung function with high safety.